

PRODUCT INFORMATION



Apraglutide (acetate)

Item No. 45070

Formal Name: L-histidylglycyl-L- α -aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L- α -aspartyl-L- α -glutamyl-L-norleucyl-D-phenylalanyl-L-threonyl-L-isoleucyl-L-leucyl-L- α -aspartyl-L-leucyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L- α -aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutamyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-L- α -asparagine, monoacetate

Synonyms: FE 203799, [Gly², Nle¹⁰, D-Phe¹¹, Leu¹⁶] hGLP-2 (1-33)-NH₂

Peptide Sequence: HGDGFSFDE-Nle-FTILDLLAARDFINWLIQTKITD-NH₂

MF: C₁₇₂H₂₆₃N₄₃O₅₂ • XC₂H₄O₂


FW: 3,765.2

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Apraglutide is supplied as a solid. A stock solution may be made by dissolving the apraglutide in the solvent of choice, which should be purged with an inert gas. Apraglutide is slightly soluble (0.1-1 mg/ml) in DMSO.

Description

Apraglutide is a peptide agonist of glucagon-like peptide 2 receptor (GLP-2R).¹ It activates GLP-2R in a reporter assay using HEK293 cells expressing the human or rat receptor (EC₅₀s = 0.03 and 0.07 nM, respectively). Apraglutide is selective for GLP-2R over GLP-1R (EC₅₀ = >1,000 nM) and a panel of 73 receptors, five ion channels, and three transporters at 1 μ M. Subcutaneous administration of apraglutide (5 mg/kg) increases intestinal length, small intestinal weight, villus height, and crypt depth and reduces fecal fat levels in a neonatal pig model of short bowel syndrome induced by intestinal and ileal resection.²

References

- Hargrove, D.M., Alagarsamy, S., Croston, G., *et al.* Pharmacological characterization of apraglutide, a novel long-acting peptidic glucagon-like peptide-2 agonist, for the treatment of short bowel syndrome. *J. Pharmacol. Exp. Ther.* **373**(2), 193-203 (2020).
- Slim, G.M., Lansing, M., Wizzard, P., *et al.* Novel long-acting GLP-2 analogue, FE 203799 (apraglutide), enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum. *J. Parenter. Enteral Nutr.* **43**(7), 891-898 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/09/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM